The Zydus Group on Wednesday said it has received the US Food and Drug Administration's (USFDA) approval for the Phase I clinical trial of Zydpla 1, a next generation anti-diabetic solution.
Zydpla 1 is an orally active, small molecule New Chemical Entity (NCE), discovered and developed by the Zydus Research Centre. Unlike other once-a-day drugs, it will have a once-a-week dose and provide diabetic patients with a more convenient treatment alternative. Zydplai 1 will offer sustained action, resulting in an improved efficacy profile, the company said in a statement here.
Pankaj R. Patel, Chairman and Managing Director, Zydus Group, said that after a promising start with Lipaglyn, the company is taking another big leap forward in the area of diabetic research and long term management of Type 2 diabetes.
The number of diabetics in the world is estimated to be over 360 million. In 2025, nearly half of the world’s diabetic population will be from India, China, Brazil, Russia and Turkey. The sales of existing drugs is expected to peak at almost $14 billion by 2022.